606 related articles for article (PubMed ID: 16125469)
1. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression.
Qin H; Valentino J; Manna S; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; O'Malley BW; Chatterjee SK
Mol Ther; 2001 Dec; 4(6):551-8. PubMed ID: 11735339
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
4. Recombinant vaccinia virus expressing IL-2 generates effective anti-tumor responses in an orthotopic murine model of head and neck carcinoma.
Dasgupta S; Tripathi PK; Bhattacharya-Chatterjee M; O'Malley B; Chatterjee SK
Mol Ther; 2003 Aug; 8(2):238-48. PubMed ID: 12907146
[TBL] [Abstract][Full Text] [Related]
5. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
[TBL] [Abstract][Full Text] [Related]
6. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.
Chang AE; Li Q; Jiang G; Teknos TN; Chepeha DB; Bradford CR
Head Neck; 2003 Mar; 25(3):198-209. PubMed ID: 12599287
[TBL] [Abstract][Full Text] [Related]
7. Immunobiology of infection with recombinant vaccinia virus encoding murine IL-2. Mechanisms of rapid viral clearance in immunocompetent mice.
Karupiah G; Woodhams CE; Blanden RV; Ramshaw IA
J Immunol; 1991 Dec; 147(12):4327-32. PubMed ID: 1684375
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
9. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
10. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
11. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
12. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
[TBL] [Abstract][Full Text] [Related]
13. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
15. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
16. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
18. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
19. Interactions between autologous CD4+ and CD8+ T lymphocytes and human squamous cell carcinoma of the head and neck.
Okada K; Yasumura S; Muller-Fleckenstein I; Fleckenstein B; Talib S; Koldovsky U; Whiteside TL
Cell Immunol; 1997 Apr; 177(1):35-48. PubMed ID: 9140094
[TBL] [Abstract][Full Text] [Related]
20. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
Janke M; Peeters B; Zhao H; de Leeuw O; Moorman R; Arnold A; Ziouta Y; Fournier P; Schirrmacher V
Int J Oncol; 2008 Oct; 33(4):823-32. PubMed ID: 18813797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
